Skip to main content

MRNS

Stock
Health Care
Biotechnology

Performance overview

MRNS Price
Price Chart

Forward-looking statistics

Beta
1.95
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.

Company info

SectorHealth Care
IndustryBiotechnology
Employees154
Market cap$83.5M

Fundamentals

Enterprise value—
Revenue—
Revenue per employee—
Profit margin—
Debt to equity—

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)—
Dividend per share—
Revenue per share—
Avg trading volume (30 day)—
Avg trading volume (10 day)—
Put-call ratio—

Macro factor sensitivity

Growth+1.8
Credit+4.2
Liquidity-0.1
Inflation+0.1
Commodities-1.1
Interest Rates-1.1

Valuation

Dividend yield0.00%
PEG Ratio—
Price to sales—
P/E Ratio—
Enterprise Value to Revenue—
Price to book—

Upcoming events

Next earnings day—
Next dividend day—
Ex. dividend day—

News

Marinus Pharmaceuticals (MRNS) Upgraded to Buy: Here's What You Should Know

Marinus Pharmaceuticals (MRNS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research (January 10, 2025)
3 Micro-Caps Set for Major Moves: Balancing Risk and Opportunity

Micro-cap stocks can come in many shapes and sizes. Some might be once successful firms that lost their way and are looking to recover their prior glory.

Benzinga (October 16, 2024)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free